000			05833nam a22003855i 4500
999			_c77850 _d77850 _x1
001			77850
003			ES-MaUEC
005			20230207040247.0
007			cr nn 008mamaa
008			150130s2014 xxu| s |||| 0|eng d
020			_a9781493912896
024	7		_a10.1007/978-1-4939-1289-6 _2doi
040			_dES-MaUEC
050		4	_aRM151 _b.S534 2014
100	1		_aShah, Vinod P. _eeditor literario _986809 _0Local
245	1	0	_aTopical Drug Bioavailability, Bioequivalence, and Penetration _cedited by Vinod P. Shah, Howard I. Maibach, John Jenner.
250			_a2nd ed. 2014.
260			_aNew York _bSpringer International Publishing _c2014
300			_a1 recurso en línea (XIII, 402 p.) _b64 ilustraciones, 16 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_a1 Percutaneous Absorption -- 2 Animal Models for Percutaneous Absorption -- 3 Mitigating Dermal Exposure to Agrochemicals -- 4 Importance of In Vitro Drug Release -- 5 Diffusion Cell Design -- 6 In Vitro Product Quality Tests and Product Performance Tests for Topical and Transdermal Drug Products -- 7 Safety and efficacy testing of topical products; Practical considerations -- 8 Challenges in Evaluating Bioequivalence of Topical Dermatological Drug Products -- 9 Methods for the Assessment of Bioequivalence of Topical Dosage Forms: Correlations, Optimization Strategies and Innovative Approaches -- 10 Application of Microdialysis in Assessing Cutaneous Bioavailability -- 11 Follicular Drug Penetration -- 12 Development of Pilosebaceous Unit-Targeted Drug Products -- 13 Deep Percutaneous Penetration into Muscles and Joints: Update -- 14 Efficacy & Toxicity of Microneedle based devices -- 15 Mathematical Models for Topical and Transdermal Drug Products -- 16 Transdermal Patches: An Industrial Perspective on the Relevance of in vitro Skin Permeation Studies and Approaches on Design of Manufacturing Processes -- 17 Transdermal Drug Delivery Systems.Â{u04A5}gulatory Considerations:Â{u0384}A and ANDA Requirements -- 18 Transdermal Estradiol and Testosterone Transfer in Man: Existence, Models, and Strategies for Prevention -- 19 Effects of occlusion on dermal drug delivery: implications for bioequivalence measurement -- 20 Challenges with Clinical Endpoints 
oequivalence -- 21 Clinical Considerations of Bioequivalence For Topical Dermatologic Drugs -- 22 OECD Test Guideline 428 â€{u0060}method for in vitro percutaneous absorption measurement? -- 23 Bioequivalence, Quality, and Novel Assessment Technologies for Topical Products: Current Challenges and Future Prospects.
520			_aThis authoritative volume explores advances in the techniques used to measure percutaneous penetration of drugs and chemicals to assess bioavailability and bioequivalence and discusses how they have been used in clinical and scientific investigations. Seven comprehensive sections examine topics including in vitro drug release, topical drugs products, clinical studies, and guidelines and workshop reports, among others. The book also describes how targeted transdermal drug delivery and more sophisticated mathematical modeling can aid in understanding the bioavailability of transdermal drugs. The first edition of this book was an important reference guide for researchers working to define the effectiveness and safety of drugs and chemicals that penetrated the skin. This second edition contains cutting-edge advances in the field and is a key resource to those seeking to define the bioavailability and bioequivalence of percutaneously active compounds to improve scientific and clinical investigation and regulation. Â{u05A9}nod P. Shah is a pharmaceutical consultant. He was Scientific Secretary of the International Pharmaceutical Federation (FIP) and is now Chair of the FIP Regulatory Sciences Special Interest Group. Dr. Shah has served at the U.S. Food and Drug Administration and has developed several regulatory guidances for the pharmaceutical industry in biopharmaceutics and topical drug products. Howard I. Maibach is professor of dermatology at the University of California, San Francisco. He received his M.D. at Tulane University Medical School in New Orleans, Louisiana, and completed his residency and research fellowships at the University of Pennsylvania in Philadelphia, Pennsylvania. Professor Maibach is a leading authority in the fields of dermatotoxicology and dermatopharmacology, in which he has conducted research and written extensively. John Jenner is a principal scientist at The Defence Science and Technology Laboratory in the UK. He has a degree in pharmacology from the University of Manchester in Manchester, UK, and a Ph.D. from the University of Surrey, Guildford, UK. John has spent his career studying defense against and treatment of highly toxic chemicals. He has an enduring research interest in percutaneously active chemicals, whether toxic materials or drugs, and experience in the design and testing of transdermal formulations.
650		7	_2embne _9164630 _aMedicación oral
650		7	_2embne _9173033 _aMedicamentos _xAdministración
700	1		_aMaibach, Howard I _eeditor literario _937880 _0comprobar BNE20050845793
700	1		_aJenner, John _eeditor literario _986810 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4939-1289-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12843295 _b10-10-17 _c23-02-15
942			_2lcc _cLE
945			_aRM151 .S534 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11556201 _z06-04-17
988			_aEBSPRINGER
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _gxxu _h0